Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir
16 June 2020 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) (NYSE: RDY) has entered into a non-exclusive licensing agreement with US-based Gilead Sciences, Inc. that will grant Dr. Reddy's the right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India, the company said.

Dr. Reddy's will receive technology transfer from Gilead for manufacturing of this drug.

Dr. Reddy's would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization by the US Food and Drug Administration (USFDA) to treat Covid-19.

Dr. Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Its major markets include USA, India, Russia and CIS countries, and Europe.